Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 17, 2024
Product Development
Obesity newcos aim for differentiation
New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Dec 15, 2023
Discovery & Translation
GDF15 linked to severe nausea in pregnancy; plus Carvykti mechanism and more
BioCentury’s roundup of translational innovations
BioCentury | Dec 7, 2023
Politics, Policy & Law
Dec. 6 Quick Takes: Pfizer CEO excoriates university presidents on antisemitism failure
Plus: J&J’s Duato: GLP-1 space ‘too crowded’ to enter, Pfizer leaving BIO and updates from Merck KGaA, Pharvaris, Novartis, Arvinas, Seagen, EyePoint and CatalYm
BioCentury | Aug 10, 2023
Product Development
Obesity mechanisms in the clinic: which overlap, and which branch out
Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss
BioCentury | Jul 18, 2023
Finance
July 18 Quick Takes: Pfizer, Flagship to launch up to 10 single-asset programs
Plus: J&J joins the IRA litigation club and updates from Novartis, Neurogene and Renibus
BioCentury | Mar 29, 2023
Product Development
Next up in obesity therapeutics
Late-stage pipeline dominated by large pharmas, GLP-1 combinations
BioCentury | Nov 22, 2022
Finance
Nov. 22 Quick Takes: Brandon, Jeito lead €50M round for CatalYm
Plus Arvinas falls on protein degradation data and updates from Turbine, GSK, argenx and more
Items per page:
1 - 10 of 33